New hope for advanced cancers? first human trial of XL309 begins
NCT ID NCT05932862
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early-stage trial is testing a new drug called XL309, alone or with another drug (olaparib), in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors. About 429 adults will take part across multiple centers.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
XL309 (ISM3091) and olaparib
What this could lead to
If successful, this could point toward a new treatment option for people with advanced solid tumors who have run out of standard therapies.
What could go wrong
This is a very early Phase 1 trial, so the drug may not work or could have unexpected side effects. It is too soon to know if it will benefit patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Exelixis Clinical Site #1
RECRUITINGHouston, Texas, 77030, United States
-
Exelixis Clinical Site #10
WITHDRAWNKansas City, Missouri, 64111, United States
-
Exelixis Clinical Site #11
RECRUITINGGermantown, Tennessee, 38138, United States
-
Exelixis Clinical Site #12
WITHDRAWNFountain Valley, California, 92708, United States
-
Exelixis Clinical Site #13
RECRUITINGOklahoma City, Oklahoma, 73104, United States
-
Exelixis Clinical Site #14
RECRUITINGRochester, Minnesota, 55905, United States
-
Exelixis Clinical Site #15
RECRUITINGJacksonville, Florida, 32224, United States
-
Exelixis Clinical Site #16
RECRUITINGTampa, Florida, 33612, United States
-
Exelixis Clinical Site #2
WITHDRAWNHouston, Texas, 77030, United States
-
Exelixis Clinical Site #3
RECRUITINGSan Antonio, Texas, 78229, United States
-
Exelixis Clinical Site #4
RECRUITINGAustin, Texas, 78758, United States
-
Exelixis Clinical Site #5
RECRUITINGNew York, New York, 10029, United States
-
Exelixis Clinical Site #6
RECRUITINGNashville, Tennessee, 37203, United States
-
Exelixis Clinical Site #7
RECRUITINGCleveland, Ohio, 44106, United States
-
Exelixis Clinical Site #8
RECRUITINGOrlando, Florida, 32827, United States
-
Exelixis Clinical Site #9
RECRUITINGNew Brunswick, New Jersey, 08901, United States